Researchers have developed a handheld multi-material bioprinter with applications ranging from wound repair to custom prosthetics. The bioprinter, details of which were published in the journal Biofabrication, improves on earlier devices by enabling the printing of multiple materials and giving control over the properties of printed tissues. Printing multiple materials could improve tissue biomimicry and facilitate the simultaneous or sequential dispensing of different materials and cells. Researchers at the University of Victoria and University of Montreal used the device to print multiple cells, drug-releasing meshes and sensors.
Bioprinting technology has advanced over the past decade. In 2016, researchers shared details of a handheld device for surgical printing of adipose stem cells, and in 2020 another team loaded a device with pore-forming bio-ink for in situ wound dressing.
The latest study addresses some of the limitations of those older technologies. A temperature control module supports long-term printing, and print heads that allow the flow of several bio-inks enable multi-material printing, resulting in a device capable of depositing hydrogel fibers and different types of cells such as dermal fibroblasts.
Using the device, the researchers printed directly on artificially created pig skin wounds. Mohsen Akbari, one of the authors of the paper and an associate professor at the University of Victoria in Canada, explained some of the applications in an article from the Institute of Physics’ IOP Publishing. READ MORE
By Nick Paul Taylor
Source: medtechdive.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
